Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study by Irish, Ashley et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Nephrology
Open Access Study protocol
Preventing AVF thrombosis: the rationale and design of the 
Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access 
OUtcomes in REnal Disease (FAVOURED) study
Ashley Irish*1, Gursharan Dogra2, Trevor Mori3, Elaine Beller4, 
Stephane Heritier9, Carmel Hawley4,5, Peter Kerr6, Amanda Robertson7, 
Johan Rosman8, Peta-Anne Paul-Brent4, Melissa Starfield4, 
Kevan Polkinghorne6 and Alan Cass9
Address: 1Renal Unit, Royal Perth Hospital, Perth, WA, Australia, 2Renal Unit, Sir Charles Gairdner Hospital, Perth, WA, Australia, 3School of 
Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia, 4Australian Kidney Trials Network, School of Population 
Health, University of Queensland, Brisbane, Queensland, Australia, 5Department of Nephrology, Princess Alexandra Hospital, Brisbane, 
Queensland, Australia, 6Department of Nephrology, Monash Medical Centre, Melbourne, VIC, Australia, 7Department of Surgery, Monash Medical 
Centre, Melbourne, VIC, Australia, 8Renal Department North Shore Hospital, Auckland, Auckland, New Zealand and 9The George Institute for 
International Health, Sydney, NSW, Australia
Email: Ashley Irish* - ashley.irish@health.wa.gov.au; Gursharan Dogra - sharan.dogra@health.wa.gov.au; 
Trevor Mori - tmori@meddent.uwa.edu.au; Elaine Beller - e.beller@uq.edu.au; Stephane Heritier - sheritier@george.org.au; 
Carmel Hawley - Carmel_Hawley@health.qld.gov.au; Peter Kerr - peter.kerr@med.monash.edu.au; 
Amanda Robertson - Amanda.Robertson@mh.org.au; Johan Rosman - johan.rosman@waitematadhb.govt.nz; Peta-Anne Paul-
Brent - p.kerr@uq.edu.au; Melissa Starfield - m.starfield@sph.uq.edu.au; Kevan Polkinghorne - kevan.polkinghorne@med.monash.edu.au; 
Alan Cass - acass@george.org.au
* Corresponding author    
Abstract
Background: Haemodialysis (HD) is critically dependent on the availability of adequate access to
the systemic circulation, ideally via a native arteriovenous fistula (AVF). The Primary failure rate of
an AVF ranges between 20–54%, due to thrombosis or failure of maturation. There remains limited
evidence for the use of anti-platelet agents and uncertainty as to choice of agent(s) for the
prevention of AVF thrombosis. We present the study protocol for a randomised, double-blind,
placebo-controlled, clinical trial examining whether the use of the anti-platelet agents, aspirin and
omega-3 fatty acids, either alone or in combination, will effectively reduce the risk of early
thrombosis in de novo AVF.
Methods/Design: The study population is adult patients with stage IV or V chronic kidney disease
(CKD) currently on HD or where HD is planned to start within 6 months in whom a planned upper
or lower arm AVF is to be the primary HD access. Using a factorial-design trial, patients will be
randomised to aspirin or matching placebo, and also to omega-3 fatty acids or matching placebo,
resulting in four treatment groups (aspirin placebo/omega-3 fatty acid placebo, aspirin/omega-3
fatty acid placebo, aspirin placebo/omega-3 fatty acid, aspirin/omega-3 fatty acid). Randomisation
will be achieved using a dynamic balancing method over the two stratification factors of study site
and upper versus lower arm AVF. The medication will be commenced pre-operatively and
continued for 3 months post surgery. The primary outcome is patency of the AVF at three months
Published: 21 January 2009
BMC Nephrology 2009, 10:1 doi:10.1186/1471-2369-10-1
Received: 7 December 2008
Accepted: 21 January 2009
This article is available from: http://www.biomedcentral.com/1471-2369/10/1
© 2009 Irish et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
Page 2 of 12
(page number not for citation purposes)
after randomisation. Secondary outcome measures will include functional patency at six and twelve
months, primary patency time, secondary (assisted) patency time, and adverse events, particularly
bleeding.
Discussion: This multicentre Australian and New Zealand study has been designed to determine
whether the outcome of surgery to create de novo AVF can be improved by the use of aspirin and/
or omega-3 fatty acids. Recently a placebo-controlled trial has shown that clopidogrel is effective
in safely preventing primary AVF thrombosis, but ineffective at increasing functional patency. Our
study presents significant differences in the anti-platelet agents used, the study design, and surgical
and patient demographics that should contribute further evidence regarding the efficacy of anti-
platelet agents.
Trial Registration: Australia & New Zealand Clinical Trials Register (ACTRN12607000569404).
Background
The incidence and prevalence of severe chronic kidney
disease (CKD) is increasing due to ageing of the popula-
tion and co-morbid conditions such as diabetes. Haemo-
dialysis is the chosen renal replacement therapy for 70%
of patients with end-stage kidney disease (ESKD) in Aus-
tralia. However, effective haemodialysis is critically
dependent upon obtaining and maintaining repeated
access to the circulation. Delivering the required blood
flow (>300 ml/minute) necessary for haemodialysis has
long been referred to as the "Achilles' heel" of dialysis.
Vascular access options include native arterio-venous fis-
tula (AVF), synthetic arterio-venous graft (AVG) or central
venous catheter (CVC). AVF is universally acknowledged
as the optimal access option with the best long-term pat-
ency, lowest cost and lowest infection rate [1-3] and is the
most prevalent access used in Australasia (75%)[4].
Because vascular access related surgical procedures and
complications of vascular access represent a high propor-
tion of all admissions in the ESKD population and are a
major economic burden for health care providers[5], var-
ious international initiatives have made this a focus of
quality care improvements[6].
Several studies confirm the risk of all cause death with
artificial vascular access devices, compared with AVF as
the reference group, is around 1.5 for AVG and 3 for CVC,
with similar rates for infectious mortality [2,3,7]. The
complications associated with AVG and CVC use are sep-
sis, especially staphylococcal, vascular malfunction
(thrombosis) and death. The increased risk of death is
directly attributable to sepsis and the need for interven-
tions to restore patency which in themselves enhance the
risk of infection. Furthermore, in comparison with AVF,
CVC and AVG have a significantly increased frequency of
interventions to maintain patency (assisted patency).
Therefore, while the clinical imperative is to establish AVF
in as many patients as possible, primary failure because of
early thrombosis and failure of maturation are the major
impediments to clinical success[8]. Reports in the litera-
ture from the 1970s and 1980s generally describe primary
failure rates of between 10 – 20%. A recent meta-analysis
examining the primary failure rate of AVF estimated the
pooled primary failure rate at 15.3% [9]. However, this
meta-analysis included studies back to the 1960s and
omitted studies published after the meta-analysis. More
contemporary publications are less encouraging with
reports of the primary failure rate between 20 – 54%[1].
Consistent with these findings of a high early failure rate,
50% of new patients commence haemodialysis in Aus-
tralia and New Zealand with a CVC, due to a failed or
inadequate AVF[10]. The higher rate of primary failure in
the more recent era may reflect changing patient factors –
such as older patients and a higher prevalence of diabetes.
Primary failure usually occurs as a result of one of two
processes; 1) thrombosis, which usually occurs within
weeks of the procedure; 2) inadequate size of the artery or
maturation of the vein[8]. Strategies to reduce primary
failure rates may therefore include pre-operative identifi-
cation of unsuitable anatomy by the use of ultrasound,
improved surgical technique and pharmacological inter-
ventions designed to prevent vessel occlusion (thrombo-
sis).
Early thrombosis is defined as thrombosis within the first
30 days post-operatively[11]. There have been a number
of small trials evaluating pharmacological agents aimed at
reducing the early thrombosis rate. These trials utilised the
anti-platelet agents, aspirin, sulphinpyrazone and ticlopi-
dine and varied in size from as few as 5 patients up to 261
patients. Andrassey et al (n = 92) compared patients given
aspirin 500 mg/day for 4 weeks with placebo: the throm-
bosis rate in the aspirin group was 4% compared with the
control group of 24%, OR 0.15 (0.03, 0.73)[12]. Another
study [13] with a smaller sample size (n = 68), did not
demonstrate a benefit from aspirin. In a study using ticlo-
pidine [14], fistula thrombosis rates for the ticlopidine
versus placebo groups were 12% versus 19% (p = 0.10)BMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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respectively. Studies using sulphinpyrazone showed vari-
able results, but were underpowered with the largest study
enrolling only 36 patients[15]. Pooled data for ticlopidine
suggests a reduction in thrombosis rate from 25% to 12%
(p < 0.001)[14]. Thus although there is some data to sug-
gest that anti-platelet agents may increase the primary pat-
ency of AVF, the limited evidence base and the uncertainty
regarding the choice of agent has not supported the wide-
spread use of anti-platelet agents in the prevention of AVF
thrombosis. There is a strong clinical need to conduct an
adequately powered clinical trial to address the important
question of efficacy of anti-platelet therapy in the preven-
tion of early thrombosis of AVF. Since the inception and
launch of the FAVOURED study, a US study has been pub-
lished examining the effect of anti-platelet agent clopidog-
rel on early AVF thrombosis[16]. We have addressed the
findings of this study and their implications for
FAVOURED under Discussion below.
Two anti-platelet agents have been chosen to explore their
prevention of early thrombosis in AVFs, low dose aspirin
and omega-3 fatty acids. Aspirin has been chosen as it has
well-established anti-platelet effects, a suggestion of effi-
cacy in the limited studies to date and because it is both
inexpensive and an agent familiar to clinicians. Its use as
an anti-platelet agent is well established in clinical prac-
tice for other purposes relating to thrombosis prevention
particularly in patients with established cardiovascular
disease. Aspirin's anti-platelet effect is mediated by the
inhibition the platelet enzyme cyclo-oxygenase (COX)
resulting in blockade of the synthesis of the pro-aggrega-
tory vasoconstrictor, thromboxane A2 (TxA2).
Omega-3 fatty acids have a number of biological effects,
which make them an attractive agent for the prevention of
vascular access thrombosis. These include the inhibition
of platelet aggregation, anti-inflammatory effects and
anti-proliferative actions. Omega-3 fatty acids and aspirin
both affect the balance between the pro-aggregatory and
vasoconstrictor effects of TxA2 and the anti-aggregatory
and vasodilator effects of prostacyclin (PGI2) but the
mechanism of their effect is different. Omega-3 fatty acids
have a weaker inhibitory effect on TxA2 level, their effect
mediated by reducing the availability of arachidonic acid
(AA), a precursor of TxA2. In addition, omega-3 fatty acids
leads to an increase in PGI3 formation (anti-aggregatory
and vasodilatation effects equipotent to PGI2)[17]. The
anti-inflammatory effect of omega-3 fatty acids is medi-
ated via a reduction in leukotriene and cytokine produc-
tion. Theoretically, a combination of aspirin and omega-
3 fatty acids should result in a more favourable effect on
platelet aggregation than either agent used alone.
One study has examined the effects of low-dose aspirin in
combination with omega-3 fatty acids on whole blood
eicosanoid production[17]. This study demonstrated an
additive  effect of the combination on TxA2 (40% with
aspirin alone vs. 62% with the combination) and a
smaller reduction in the concentrations of PGI2 and PGI3
compared with aspirin alone. There has only been one
study exploring the efficacy of omega-3 fatty acids in the
prevention of vascular access thrombosis. This study
involved the use of omega-3 fatty acids as a single agent
and only explored its use in AVG, not AVF. Importantly,
the study demonstrated a substantial reduction in throm-
bosis at 1 year in patients with AVG[18]. There are other
effects of omega-3 fatty acids, which may be particularly
beneficial in patients with CKD. Omega-3 fatty acids has
been shown to result in an improvement in lipid profile
[18-20], to reduce BP and heart rate[21], and to attenuate
inflammatory responses [22] and oxidative stress[23].
Other postulated but as yet unproven benefits in the CKD
population include a reduction in inflammatory
response, cardiovascular mortality and a reduction in
uraemic pruritis[24].
The relationship between aspirin use and bleeding is a
potential concern for clinicians in patients with CKD.
Even in the general population, the use of a chronic low
dose of aspirin doubles the risk of serious gastrointestinal
bleeding [25] and the theoretical risk may be higher in
patients with CKD because of the presence of uraemic
induced impairment of haemostasis. There have been
published studies[26,27], showing a significant elevation
in bleeding times in patients on haemodialysis treatments
administered a single dose of aspirin, but surprisingly lit-
tle evidence-based clinical trial data in this population.
This has more recently been explored in the UK-HARP-I
study. In this factorial design study involving simvastatin
and aspirin as active therapies, allocation to the aspirin
group was not associated with an excess of major bleeds
(2% in patients on aspirin vs. 3% in patients not on aspi-
rin), but there was a three-fold increase in minor bleed-
ing[28]. Importantly though, in this study, patients
received aspirin for 12 months, whereas our study has a
much shorter period on therapy of 3 months. In addition,
patients on dialysis undergoing renal transplantation
have successfully received pre-operative aspirin for the
prevention of graft thrombosis without an increased risk
of major bleeding [29,30].
Omega-3 fatty acids appear to be well tolerated, even in
high doses, with gastrointestinal complaints particularly
nausea, vomiting, diarrhoea and non-specific discomfort
being the most often reported. In studies looking at the
effect of omega-3 fatty acids on bleeding time it has not
been found to be significantly prolonged [31]. In studies
that have been done thus far in the CKD cohort, there
have been no clear effects demonstrated in relation to
platelet aggregation and bleeding times. There has onlyBMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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been one report of a serious bleeding event in a single
patient in an uncontrolled study[32]. Furthermore, it has
been reported that administration of omega-3 fatty acids
can protect the gastric mucosa against aspirin-induced
injury, the postulated mechanism being that omega-3
fatty acids counteracts the effect of aspirin on the decrease
in prostacyclin (combined effect of PGI2 and PGI3)[33].
This is supported by clinical data suggesting that omega-3
fatty acids decreases gastric erosions and ulcers caused by
aspirin or alcohol[34]. Thus the combination of aspirin
and omega-3 fatty acids may be expected to be additive in
terms of efficacy in vascular access thrombosis, but to
have a lower risk of bleeding complications than the use
of aspirin alone.
We have chosen an oral route of administration for both
aspirin and omega-3 fatty acids in this study. The choice
of 100 mg for aspirin is based on this dose having ade-
quate anti-platelet aggregation properties and is the dose
most commonly used in patients with cardiovascular dis-
ease. A 100 mg dose is readily available. The dose of
omega-3 fatty acids (4 g daily) has been shown to be well
tolerated and improve cardiovascular risk factors in
patients at increased risk of cardiovascular disease [35-
39]. The marine derived omega-3 fatty acids (commonly
known as fish oils) capsules chosen (Omacor©), are com-
mercially available and provide the highest concentration
of omega-3 fatty acids per gram of oil. The oral absorption
of both agents is excellent and thus alternative routes of
administration are not required.
The design of a factorial study is based on the hypothesis
that aspirin and omega-3 fatty acids will both be effective
therapies and that the combination of aspirin and omega-
3 fatty acids will be additive, but not synergistic. In rela-
tion to safety concerns, although both aspirin and omega-
3 fatty acids prolong bleeding time, the combination may
be expected to be safer than when aspirin is used alone.
Methods/Design
Ethics approval for the Omega-3 fatty acids (Fish Oils)
and Aspirin in Vascular access OUtcomes in REnal Dis-
ease (FAVOURED) trial has been obtained from several
local Human Research Ethics Committees and will be
obtained in all participating centres prior to study initia-
tion and patient enrolment. The study will be performed
in accordance with the 2000 Edinburgh, Scotland Revi-
sion of the Declaration of Helsinki, the National Health
and Medical Research Committee (NHMRC) Statement
on Human Experimentation, Joint NHMRC/AVCC State-
ment and Guidelines on Research Practice, applicable
ICH guidelines and the Therapeutic Goods Administra-
tion (TGA). The trial has been registered with Australia &
New Zealand Clinical Trials Register (ACTRN1260700056
9404).
Study Design
This is a factorial-design trial, where patients are ran-
domised to aspirin or matching placebo, and also to
omega-3 fatty acids or matching placebo, resulting in four
treatment groups (Figure 1). Randomisation will be
achieved using a dynamic balancing method, balancing
over the two stratification factors of 1) study site and 2)
upper versus lower arm AVF.
Each of the two interventions will be studied using a
matching placebo, in order to make this a double-blind
trial. At the completion of treatment, patients and investi-
gators will be asked which treatment they believe the
patient has been receiving, in order to have a measure of
the degree of effectiveness of blinding. Two independent
observers will make the primary outcome of patency
assessment, unaware of the patient's treatment assign-
ment and treatment course or medical history.
Patient Population
The study will be multi-centre, and open to all public and
private hospital renal units that perform vascular access
procedures. The study will be conducted in Australia and
New Zealand. In the future international collaboration
with sites in Asia and the United Kingdom will be consid-
ered.
Patients must meet the following inclusion and exclusion
criteria:
Inclusion criteria include
The Study population will include adults with the follow-
ing inclusion criteria:
1. Stage 4 or 5 Chronic Kidney Disease
2. Currently on haemodialysis or haemodialysis is
planned to start within 6 months (including patients cur-
rently on peritoneal dialysis).
3. Planned AVF will be the primary haemodialysis access
mechanism.
4. Surgery to create an arterio-venous fistula in the upper
or lower arm is planned.
5. Aged over 19 years
6. Treating team agreeable to patient's involvement in the
trial and the patient has given informed consent
Exclusion criteria include
1. Revision of existing AVF rather than de novo AVFBMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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Schema for the FAVOURED Trial Figure 1
Schema for the FAVOURED Trial.
Patient Population 
Inclusion: 
  Stage 4 or 5 CKD patients undergoing HD with planned 
primary de novo AVF 
Exclusion: 
-  non primary AVF creation or revision. 
-  medical indication for anti-platelet agents or known 
intolerance of agents. 
Stratification 
-  upper vs. lower arm site 
-  study centre 
RANDOMISATION
ARM A 
Aspirin & Omega-3 
fatty acids 
ARM B 
Aspirin placebo and 
Omega-3 fatty acids 
ARM C 
Aspirin and Omega-
3 fatty acids placebo 
ARM D 
Aspirin placebo & 
Omega-3 fatty acids 
placebo 
Endpoints 
Primary Endpoint:   - patency of AVF at 84 days post creation 
Secondary Endpoints:  - functional patency of AVF at 6 & 12 months post creation  
- primary patency time 
- secondary patency timeBMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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2. Medical indication for anti-platelet or thrombolytic
agents
3. Known intolerance of agents including hypersensitivity
to aspirin, allergy to any other NSAIDs or fish
4. Current use of aspirin within two weeks of commenc-
ing trial, or of omega-3 fatty acids within 4 weeks of com-
mencing trial
5. Pregnancy, lactation or intention to fall pregnant dur-
ing the time course of the study
6. Known bleeding disorder or established diagnosis of
active or suspected bleeding
7. History of GI ulcers or bleeding within the last 3
months
8. Platelet count less than 100 × 109 /L
9. Known active peptic ulcer disease
10. Severe hepatic insufficiency
11. Already receiving anti-coagulation therapy such as
warfarin
12. Receiving regular non-steroidal anti-inflammatory
(NSAIDS) agents for another indication such as arthritis
13. Syndrome of asthma, rhinitis and nasal polyps if
uncontrolled on usual therapy
14. Plan to have other (non-access) surgery within 2
weeks of trial medication period where in the opinion of
the investigator aspirin or omega-3 fatty acids would be
contraindicated for the planned procedure.
15. Potential non-compliance with treatment regimen in
the view of the treating clinicians
16. Involved in another clinical trial where the interven-
tion being trialled is likely to confound the outcome of
this trial
17. Previously randomised to this trial.
Outcome measures
The primary outcome measure is (unassisted) patency of
the AVF at three months after randomisation. This is
defined as the presence of an audible bruit throughout
systole and diastole over the site of the arterio-venous
anastomosis, without the need for surgical or radiological
intervention from the time of creation until the time of
assessment. The assessment of patency will be made at
this time even if the AVF is not yet used for haemodialy-
sis[11].
Secondary outcome measures
1. Functional patency at 6 months. This is defined as the
ability to use the AVF for dialysis to the satisfaction of the
clinician(s), without the need to use alternative dialysis
access, or to delay commencement of dialysis due to
access unsuitability.
2. Functional patency at 12 months. This is defined as for
the outcome measure functional patency at 6 month but
is intended to capture the results of patients whose com-
mencement of dialysis is delayed beyond 6 months. In
patients who have not needed to start dialysis, assessment
of functional patency will be delayed until commence-
ment of dialysis.
3. Time to failure of primary patency: Time from AVF cre-
ation to need for first intervention. An event is defined as
revision surgery, need for alternative access, or abandon-
ment of AVF whichever comes first. Censored observa-
tions are defined as regaining renal function such that
dialysis is not needed or still having a patent AVF at time
of study analysis. There will be a minimum of 12 months
follow up time for each patient.
4. Time to failure of assisted patency. This is defined as
time from AVF creation to abandonment of access. That is,
radiological and surgical interventions to preserve or
restore patency do not constitute failure. An event is
defined as abandonment of the AVF as dialysis access.
Censored observations will be as for time to failure of pri-
mary patency above.
5. Adverse events. All serious adverse events will be col-
lected. The analysis of this secondary outcome will focus
particularly on bleeding events.
Exploratory outcome measures are also defined, in order
to confirm the validity of the primary outcome measure,
and to provide a means of comparison with other previ-
ous trials:
1. Patency in the first 24 hours post surgery: determined
by the presence or absence of a bruit over the site of the
anastomosis, with standard stethoscope.
2. Patency at 6 weeks post surgery: determined by the pres-
ence or absence of a bruit over the site of the anastomosis.
3. Time to first cannulation of the AVF: time taken as time
of surgery until the first attempt at access cannulation.BMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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4. Time to consistent cannulation of the AVF: time taken
as the time from surgery until that of the 3rd consecutive
dialysis session with successful cannulation of the access.
Study Procedures
Participants will be recruited from public and private hos-
pital renal units providing haemodialysis and vascular
access services in Australia and New Zealand. Patients will
meet the inclusion and exclusion criteria and be sched-
uled to undergo surgery for creation of a de novo AV fis-
tula. Processes to identify and screen all potential recruits
will be established within each centre with consultation
with the Trial Management Committee.
Patient consent forms will be approved by the Human
Research Ethics Committee at each participating site prior
to the beginning of the trial. A sample consent form and
patient information sheet is provided to participating
sites. Participating sites will file a copy of the approved
consent form and information sheet for their site with the
coordinating office. After discussing the trial, ample time
will be given to the participant, accompanying person or
legal representative to inquire about the trial and decide
whether to participate. No person involved with the trial
will coerce or unduly influence the decision of a patient to
participate in a trial. A copy of the signed consent form
and the patient information sheet will be supplied to the
participant. Patient consent must be obtained prior to the
registration or initiation of trial procedures. Patients will
not be randomised until a signed consent form is filed at
site and notification is received by the coordinating office.
The Trial Management Committee will monitor the med-
ical literature, and any other relevant information impact-
ing on the continuation of the trial. Consent forms and
patient information sheets will be revised should any rel-
evant and important new information become available.
Registration will occur when subjects come for their surgi-
cal consultation prior to the operation to create the AVF.
The patient will have an initial consultation with a study
renal physician or surgeon to discuss study participation.
This will include a preliminary eligibility check. Consent-
ing patients will be registered by emailing or faxing a com-
pleted registration form to the coordinating centre. The
registration form also serves as notification of completion
of a patient consent form. The patient will also be ran-
domised at this time. Stratification will occur for study
site, incident versus prevalent patient status and upper vs.
lower arm site. Patients will be randomised to one of four
treatment groups in equal proportion.
Please refer to table 1 for an outline of the timing of the
study visits study assessments preformed at those visits.
Treatment plan and modifications
The study treatment commences on the day prior to the
scheduled AVF surgery and will continue for 3 months.
Participants will take 100 mg of Aspirin per day p.o. or
matching placebo and 4 g of omega-3 fatty acids in
divided doses (2 g twice daily) in the form of Omacor cap-
sules, 45% eicosapentaenoic acid (EPA) and 45% docos-
apentaenoic acid (DHA), or matching placebo.
Table 1: Outline of Favoured Study Procedures
Study Visits Baseline Randomisation Surgery Treatment Period (wks) Follow-up
(mths)
Assessment ≤ 4 wks prior to 
surgery
≤ 7 Days prior to 
surgery
1 6 1 2 61 21 82 43 03 6
Informed Consent X
Study Medication 
Allocated
X
Medical History and 
Physical Exam
X
W e i g h t  &  B l o o d  P r e s s u r e X X X X X XXXXXX
Demographics X
D i a l y s i s  s t a t u s X X X X XXXXXX
Description and status of 
AVF
X X X X XXXXXX
Concomitant meds X X X X X X
Adverse events X X X X X
Routine fasting blood & 
urine samples
XX
Batched blood & urine 
samples
XX XBMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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Compliance will be monitored by capsule/tablet count at
scheduled study visits at week 1, 6 and 12. Selected centres
will also measure erythrocyte fatty acids for compliance
with omega-3 fatty acid intake and urinary thromboxane
B2 levels (for patients with urine output) for compliance
with aspirin intake. Centres will apply routine biochemis-
try (lipids, CRP) and haematology analyses as part of
patient monitoring.
Study treatment may be discontinued if one of the follow-
ing occurs:
1. A major bleeding event (e.g. haemorrhagic stroke, gas-
tro-intestinal bleed);
2. The access is abandoned due to thrombosis at any time
after the one week assessment;
3. An AVG rather than an AVF is created, or a vein graft is
used;
4. Anti platelet therapy or anticoagulation is indicated
because of other co morbid events i.e. for example a major
cardiovascular event;
5. A female patient becomes pregnant while on study
medication. The event should be reported to the trial
coordinating centre immediately as a medically important
SAE. The event will be reported to Bayer Safety within 24
hours by the coordinating centre and follow up per-
formed through to delivery;
6. The AV anastomosis is created in the lower limbs rather
the upper limbs during surgery.
7. Patient receives renal transplant
Study treatment should be continued if:
1. Further access is created (including a new AVF or AVG,
peritoneal and venous catheter) because of failure of mat-
uration of the study AVF, i.e. access is still patent;
2. Renal function is recovered; the study AVF can still be
measured for patency.
No other anti-platelet or anti-coagulation agent will be
permitted during the period the patient is taking study
medication.
Statistical Considerations
Sample size calculation for the primary outcome
The event rate for the primary outcome (failure of primary
patency) is estimated to be 25% at three months in the
control group. If a 30% relative risk reduction is achieva-
ble with either aspirin or omega-3 fatty acids, then with
80% power and a significance level of 5%, 1200 study
subjects will be required (300 receiving double placebo,
300 active aspirin and placebo omega-3 fatty acids, 300
active omega-3 fatty acids and placebo aspirin, and 300
both active aspirin and active omega-3 fatty acids in a fac-
torial design). This allows for 5% drop-in from placebo to
active treatment (either aspirin or omega-3 fatty acids),
5% drop-out from study treatment (to no treatment –
assumed equivalent to placebo), and 5% loss to follow-
up. This is equivalent to an observed relative risk reduc-
tion of 24%. Without adjustment for compliance, the
study size needed would have been 932 subjects.
The study is not adequately powered to detect a clinically
important difference between the combination of aspirin
and omega-3 fatty acids and either treatment alone, but
preliminary data on the combination will be obtained.
The event rate of the primary outcome, primary failure, is
based on review of all papers published in this area. The
effect size, a 30% reduction, is based on the smallest size
of the effect the proposing clinicians believe would lead to
a change in practice (incorporation of intervention)
should the trial prove the intervention is efficacious.
Sample size calculation for the secondary outcome
Sample size is estimated for the secondary outcome (fail-
ure of patency at 6 months) under assumptions of addi-
tive or multiplicative effects for each of 3 placebo rates.
The calculation below is based on the following assump-
tions: 5% loss to follow up, 15% drop-in and 5% drop-
out. The baseline failure rate of patency at 6 months is
(40%, 50% and 60%) in the placebo group, the use of
either aspirin or omega-3 fatty acids alone results in a rel-
ative risk reduction (RRR) of 25%, i.e. the failure rate
becomes respectively 30%, 37.5% and 45% for a patient
taking only one drug.
The sample size calculation is based on a marginal analy-
sis (Z-test) with two-sided α = 0.05, power β = 90%. Table
2 presents required sample sizes under additive model
(bold) and under multiplicative model
A recently published comparable trial in the United States
[16] experienced a placebo rate of 60% for failure of pat-
ency at 6 months. We are confident that a sample size
based on a placebo rate of at least 50% is a realistic esti-
mate and that the sample of 1,200 recruited for the pri-
mary outcome will generally be adequate for the
secondary outcome whether the effect is additive or mul-
tiplicative.
Recruitment
Based on data from the ANZDATA renal registry[40],
7,202 patients were receiving dialysis in Australia andBMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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New Zealand in December 2004. Importantly, 2042
patients commenced dialysis in Australia and New Zea-
land in the calendar year 2004. Data obtained from the
whole of New Zealand population and access rates for
Princess Alexandra Hospital (PAH), Queensland, reveal
that 1 procedure is performed per year for every 2.3 – 2.8
patients receiving haemodialysis (total numbers of
patients – new patients and prevalent patients). The New
Zealand data was obtained by Dr. Mark Marshall (survey
from October 1 2000 until September 30, 2001) and by
Dr. Carmel Hawley (Queensland) based on prospectively
collected data in PAH renal unit from January 2004 until
December 2004. In addition further information from the
2005 registry report supports these data. Incident patients
require access for dialysis and 27% and 33% of haemodi-
alysis patients in Australia and New Zealand, respectively,
were incident patients in 2004. Thus we can expect these
patients at the very least to require new vascular access, in
addition to existing patients on dialysis who need further
access because of failure of previous vascular access proce-
dures. Extrapolation to the whole Australian and New
Zealand population, using a conservative estimate of 1
procedure per 3 patients allows us to derive that 2,400
access procedures are performed per year (AVF and AVG).
Using a conservative estimate that 75% of access is AVF
and not AVG, gives an estimation of 1,800 de-novo AVF
creations per year. Assuming we will recruit 22% of these,
recruitment should take approximately three years.
This trial is to be conducted by the Australasian Kidney
Trials Network (AKTN). The Australian and New Zealand
Society of Nephrology, and Kidney Health Australia were
instrumental in the development of the AKTN, which is
supported by all the major renal units in Australia and
New Zealand. The Scientific Committee is representative
of the majority of large renal units in Australia and New
Zealand. Moreover, the trial has been developed to be as
inclusive as possible with an early and relevant primary
end-point which should also encourage enrolment. In
addition, the Australian and New Zealand renal commu-
nity has a keen focus on vascular access which has been
the subject of a number of recent seminal publications in
the area of vascular access. Thus we are confident this trial
will be well supported by renal units in Australia and New
Zealand.
Analysis
Analysis of the primary outcome (patency) will be on an
intent-to-treat basis. All randomised patients will be ana-
lysed in the group they were allocated to, even if they do
not receive treatment as allocated, or do not commence
treatment. All randomised patients will be included in the
analysis.
The primary outcome is measured as the proportion with
failure of patency at three months after randomisation.
The primary hypothesis will be tested using a chi-square
test of proportions to test the null hypotheses that a) the
proportion of failures in those allocated to aspirin versus
those allocated to placebo aspirin is equal, and b) the pro-
portion of failures in those allocated to omega-3 fatty
acids versus those allocated to placebo omega-3 fatty acids
is equal. The primary outcome will be measured at 84
days after randomisation, with a permitted tolerance of 7
days prior, and 14 days after the due date of 84 days. Tests
of hypotheses will be at the 5% significance level, and 2-
sided p-values will be used.
Any patient who does not have a 84-day measure will be
counted as failure of patency in the primary analysis. A
secondary analysis will be done including only those with
a 84-day measure to test the sensitivity of the analysis of
the main treatment comparisons to patient exclusions. As
this is a short-term intervention, with a relatively short
recruitment period, the only planned interim analysis is
of safety. This will be conducted at 1/3 and 2/3 of total
patient numbers accrued. Similar analyses to the primary
one will be undertaken on the secondary outcomes, as
well as exploratory analyses looking at the validity of the
chosen primary outcome and its correlation with other
outcomes, and the prediction of thrombosis from base-
line variables such as markers of inflammation.
Table 2: The sample sizes required under the additive and multiplicative models for the secondary outcome – functional patency
Total sample size
Additive model Multiplicative model
Patency failure rate at 6 months for placebo group unadjusted adjusted unadjusted adjusted
40% 874 1455 1156 1812
50% 620 1034 820 1297
60% 452 752 596 941
(Unadjusted and adjusted refer to the calculations of sample size without and with adjustment for loss to follow-up (5%), drop-in (15%) and drop-
out (5%))BMC Nephrology 2009, 10:1 http://www.biomedcentral.com/1471-2369/10/1
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Discussion
This multicentre Australian and New Zealand study has
been designed to determine whether the outcome of sur-
gery to create AVF can be improved by the use of aspirin
and/or omega-3 fatty acids. Vascular access failure is a sig-
nificant problem for patients receiving dialysis because it
increases their risk of infection, hospitalisation and death.
The economic costs of the increased hospitalisations aris-
ing from inadequate or artificial vascular access are con-
siderable. Effective therapies to prevent failure of primary
AVF are therefore warranted. The therapies nominated in
the FAVOURED study are widely available and inexpen-
sive.
It is an appropriate time to study the effects of anti-platelet
agents in the prevention of AVF thrombosis. The number
of patients requiring dialysis is growing and contempo-
rary studies of the natural history of vascular access out-
comes show an increase in the incidence of primary
failure, which is most likely related to an increasing prev-
alence of older patients with comorbidities such as diabe-
tes. At the time of inception of the FAVOURED study,
there were no adequately powered studies examining the
efficacy of anti-platelet agents in the prevention of AVF
thrombosis. Subsequent to FAVOURED being launched
in Australia and New Zealand, a US group has published
a placebo-controlled parallel arm study examining the
prevention of early thrombosis in AVFs using Clopidogrel
(an antiplatelet agent) with study treatment commencing
one day post surgery with a primary outcome of patency
at 6 weeks [16]. There was a 12.2% thrombosis rate in the
Clopidogrel arm vs. 19.5% in the control arm: RR of 0.63
(0.46–0.97) p = 0.018, adjusted for interim analyses. Suit-
ability of the AVF for dialysis failed in 63% of the clopi-
dogrel group and in 60% of the placebo group (61%
overall). There were no differences in adverse events and,
surprisingly, bleeding events were very low in both trial
arms. The conclusions drawn by the investigators were
that although Clopidogrel is effective in safely preventing
primary AVF thrombosis, it was ineffective at increasing
functional patency and therefore cannot be recom-
mended.
The implications this trial for the FAVOURED Study
include the following:
1. The high functional failure rate is especially concerning
and much higher than expected. This may reflect aspects
related to surgical (e.g. small number of procedures per-
formed by individual surgeons) and nursing care (nee-
dling skills for AVF) in the US and/or patients
demographics. Furthermore, significant variation
between USA and both European and Australian clinical
practice could explain the high US study failure and
unsuitability rates. In this context, the generalisability of
this American study to other countries is uncertain and
justifies additional trial confirmation in other countries;
2. Earlier administration of the active agents before sur-
gery (as in FAVOURED) rather than after may lead to an
even greater efficacy in relation to the primary thrombosis
rate;
3. The rational for trialing two agents in a factorial design
remains valid. Omega-3 fatty acids may be of an addi-
tional benefit to aspirin by improving vascular endothe-
lial function and smooth muscle relaxation, which may
enhance maturation and greater attainment of functional
patency;
4. The low bleeding rates and safety data with Clopidogrel
are reassuring in the context of uncertainty regarding the
safety of anti-platelet therapy in renal failure, given that
anecdotally Clopidogrel is considered to be associated
with a higher risk of bleeding than aspirin;
5. The greater duration of follow up (minimum of 1 year)
in the FAVOURED Study will allow greater ascertainment
of the secondary outcome measure with relation to func-
tional patency. This acquires even greater importance in
view of the Clopidogrel Study result.
If the trial demonstrates a positive effect of either or both
agents, this will support routine use of these agents in clin-
ical practice and lead to a widespread reduction in throm-
bosis and an increase in functioning AVF. This has
significant patient benefits and health system benefits in
reduced costs associated with repeat hospitalisations. If
the trial demonstrates no effect of the agents, this will sug-
gest that platelet aggregation is not the major mechanism
for thrombosis in this population and that efforts to
improve AVF patency would then need to be redirected to
other mechanisms associated with access failure, such as
vascular anatomical function.
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